Enlivex Therapeutics Secures $212M Investment for Digital Asset Strategy and Leadership Enhancement

Enlivex Therapeutics Unveils Innovative Digital Asset Strategy Amidst Private Investment

Enlivex Therapeutics Ltd. embarks on a pivotal journey by securing a substantial $212 million private investment aimed at launching an innovative digital asset treasury strategy. This investment involves issuing 212 million shares at $1.00 each, a price that represents an 11.5% premium over the stock's closing price on November 21, 2025. The funds raised from this initiative are earmarked for the implementation of the RAIN prediction markets token treasury strategy, which seeks to harness the potential of decentralized finance (DeFi). This strategic move not only enhances the company’s liquidity but also emphasizes its commitment to integrating cutting-edge technology into its operational framework.

The RAIN protocol, developed on the Arbitrum network, allows users to create and trade custom options across various markets while featuring a deflationary Buyback & Burn mechanism. Enlivex Therapeutics positions RAIN as a cornerstone of its treasury strategy, aiming to establish it as the "Uniswap" of prediction markets. By fostering global participation in market creation, Enlivex not only seeks to strengthen its financial position but also aims to lead in the innovative intersection of biopharmaceuticals and digital assets. This forward-thinking approach aligns with the industry's shift towards embracing decentralized solutions, further underlining Enlivex's dedication to remain at the forefront of technological advancements within the healthcare sector.

In conjunction with this pivotal development, Enlivex Therapeutics appoints former Italian Prime Minister Matteo Renzi to its board of directors, effective November 24, 2025. This strategic appointment reflects the company’s commitment to enhancing leadership and governance as it navigates the complexities of the biopharmaceutical landscape. Chairman Shai Novik expresses optimism about Renzi's leadership potential, highlighting how such expertise can bolster shareholder value.

These developments showcase Enlivex Therapeutics' proactive stance in leveraging both financial resources and innovative technologies. By integrating RAIN into its strategy and enhancing its leadership team, the company is poised to navigate the challenges of the biopharmaceutical industry while driving future growth and innovation. This multifaceted approach underscores Enlivex’s ambition to not only advance its core immunotherapy business but also to explore new avenues in the rapidly evolving digital asset landscape.